By 2030, it is anticipated that the Italy oncology drugs market will reach a value of $10.9 Bn from $4.7 Bn in 2022, growing at a CAGR of 11.1% during 2022-2030. The oncology drug market in Italy is dominated by a few large pharmaceutical companies such as Sanofi, Novartis, Roche, and Pfizer. The oncology market in Italy is segmented into different therapeutic areas, such as breast cancer, lung cancer, colorectal cancer, prostate cancer, and others. The market is also segmented based on treatment type, such as surgery, radiation therapy, chemotherapy, and targeted therapy.
By 2030, it is anticipated that the Italy oncology drugs market will reach a value of $10.9 Bn from $4.7 Bn in 2022, growing at a CAGR of 11.1% during 2022-2030. The oncology drug market in Italy is a significant market within the European Union. Italy has a high incidence of cancer and a strong healthcare system, which drives demand for oncology drugs. In 2020, the incident number of cancer cases in Italy was 256,205. The cumulative risk of cancer was 28%, of which the maximum risk is for breast cancer i.e., 9.3%. The healthcare spending of Italy is about $173 Mn in 2020, which is 9.6% of their GDP.
Market Growth Drivers Analysis
The burden of cancer is considerable in Italy as over 180 000 people died of cancer in 2018, which is more than twice the registered number of COVID-19 deaths in 2020. Improving equity of access and quality of cancer screening programs are among the main objectives of the National Prevention Plan 2020-25, which was endorsed in August 2020. Before the adoption of this new plan, in April 2019 the government had already approved new guidelines for governance of the regional oncology networks, aimed at regulating hospital acute and post-acute care for cancer patients.
Market Restraints
Despite the fact that the Italian health system generally offers good access to high-quality care, the pandemic exposed significant structural flaws, such as long periods of underinvestment in the health workforce and the infrastructure for health information. The lengthy wait times for specialist appointments in Italy could deter some competitors from entering the market.
Key Players
May 2022: Novartis temporarily suspended the production of its Lutathera and Pluvicto cancer therapies at facilities in Italy and New Jersey after potential quality issues were discovered in their manufacturing. Lutathera and Pluvicto are both so-called radioligand therapies, a type of treatment that uses nuclear medicine to precisely target and treats cancer cells.
The Italian National Health Service is taking care of the public healthcare expenditure for oncological condition treatment. The cost of using Italy’s health insurance system is low. In-patient care and primary care are free, as is visiting a doctor. However, the public health system uses a "co-pay" system for specialist visits, diagnostic procedures, and prescription medication.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Drug class
By Therapy
By Indication
By Dosage form
By Distribution channel
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.